KeyCorp Lowers Phreesia (NYSE:PHR) Price Target to $28.00

Phreesia (NYSE:PHR) had its price objective trimmed by KeyCorp from $30.00 to $28.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. Citigroup increased their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Piper Sandler reissued an “overweight” rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group boosted their price target on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia presently has an average rating of “Buy” and a consensus target price of $31.33.

Phreesia Trading Down 0.4 %

NYSE:PHR opened at $23.86 on Wednesday. The company has a market cap of $1.40 billion, a PE ratio of -16.23 and a beta of 0.82. The business’s 50 day moving average is $26.27 and its two-hundred day moving average is $24.28. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia has a 52 week low of $17.07 and a 52 week high of $30.53.

Insider Buying and Selling

In other news, SVP Amy Beth Vanduyn sold 4,720 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $128,903.20. Following the transaction, the senior vice president now directly owns 110,309 shares of the company’s stock, valued at approximately $3,012,538.79. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Evan Roberts sold 3,519 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total transaction of $105,781.14. Following the transaction, the chief operating officer now directly owns 741,197 shares in the company, valued at approximately $22,280,381.82. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 168,791 shares of company stock valued at $4,700,424. Company insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PHR. SG Americas Securities LLC acquired a new stake in Phreesia during the first quarter worth about $462,000. Rhumbline Advisers raised its stake in shares of Phreesia by 3.8% in the first quarter. Rhumbline Advisers now owns 86,844 shares of the company’s stock valued at $2,220,000 after purchasing an additional 3,213 shares in the last quarter. GAMMA Investing LLC increased its holdings in Phreesia by 10,605.7% in the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company’s stock valued at $145,000 after buying an additional 5,621 shares during the period. Probity Advisors Inc. acquired a new position in shares of Phreesia in the 4th quarter valued at $304,000. Finally, PharVision Advisers LLC acquired a new stake in shares of Phreesia during the 4th quarter valued at about $302,000. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.